Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411482 | 0.85 | HSD17B10 (0.57) | POLBHSD17B10SMN1; SMN2NPC1KMT2A | |
| SCHEMBL5411479 | 0.85 | HSD17B10 (0.57) | POLBHSD17B10SMN1; SMN2NPC1KMT2A | |
| SCHEMBL13819936 | 0.85 | HSD17B10 (0.57) | POLBHSD17B10SMN1; SMN2NPC1KMT2A | |
| SCHEMBL29055986 | 0.83 | POLB (0.45) | POLBHSD17B10SMN1; SMN2NPC1KMT2A | |
| SCHEMBL28854901 | 0.82 | POLB (0.53) | POLBHSD17B10SMN1; SMN2NPC1KMT2A | |
| SCHEMBL12158537 | 0.81 | HSD17B10 (0.52) | POLBHSD17B10SMN1; SMN2NPC1KMT2A | |
| SCHEMBL15113629 | 0.81 | HSD17B10 (0.52) | POLBHSD17B10SMN1; SMN2NPC1KMT2A | |
| SCHEMBL5743165 | 0.81 | HSD17B10 (0.52) | POLBHSD17B10SMN1; SMN2NPC1KMT2A | |
| SCHEMBL10031609 | 0.80 | HSD17B10 (0.57) | POLBHSD17B10SMN1; SMN2NPC1KMT2A | |
| SCHEMBL903389 | 0.80 | HSD17B10 (0.57) | POLBHSD17B10SMN1; SMN2NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | POLB 4763/4885HSD17B10 2765/4885SMN1; SMN2 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.